2016 News Releases

News Releases | Events
Keyword Search
 
2017 | 2016 | 2015 | 2014
Axsome Therapeutics Reports Third Quarter 2016 Financial ResultsNovember 14, 2016NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2016. “We continued to advance our three Phase 3 trials during this quarter,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome Therapeutics. “We look forward to filing an IND for our planne... Read MoreAxsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley BankNovember 10, 2016NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that it has entered into a $20 million term loan agreement with Silicon Valley Bank. Axsome intends to use the additional capital to support the ongoing development of its late-stage clinical pipeline. “The initial $10 million tranche of the term loan will allow... Read MoreAxsome Therapeutics Announces Publication of Research Showing AXS-02 Inhibits Pain in Animal Model of Complex Regional Pain SyndromeOctober 4, 2016NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of data showing that AXS-02 (oral zoledronate) inhibits pain in a well-validated animal model of complex regional pain syndrome (CRPS). The study, conducted by researchers at the Veterans Affairs Palo Alto Health Care System and Stanford Universi... Read MoreAxsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare ConferenceSeptember 19, 2016NEW YORK, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016 at 8:30 AM Eastern Time. The conference will be held at the Sofitel New York in New York Cit... Read MoreAxsome Therapeutics to Present at Upcoming Investor ConferencesSeptember 6, 2016NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the following investor conferences: The 23rd Annual NewsMakers in the Biotech Industry Conference in New York City on Friday, September 9, 2016 at 3:30 PM Ea... Read MoreAxsome Therapeutics Announces Transition of Chief Medical OfficerSeptember 2, 2016NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced today that Randall Kaye, M.D. is transitioning from his role as Chief Medical Officer (CMO) of the Company to Senior Clinical Advisor, effective September 1, 2016. This new role allows Dr. Kaye to continue to provide his expertise to Axsome while making time for his oth... Read MoreAxsome Therapeutics Reports Second Quarter 2016 Financial ResultsAugust 9, 2016NEW YORK, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2016. “In the second quarter we continued to advance our three ongoing Phase 3 trials, and we expanded our late-stage pipeline with the receipt of positive FDA guidance on our development plans for AXS-05 in... Read MoreAxsome Therapeutics to Present at the Cantor Fitzgerald 2nd Annual Healthcare ConferenceJuly 5, 2016NEW YORK, July 05, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016 at 10:15 AM Eastern Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clinical produ... Read MoreAxsome Therapeutics Added to Russell 3000® and Russell 2000® IndexesJune 27, 2016NEW YORK, June 27, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, as part of the Russell US Indexes annual reconstitution, effective after the US market opens on June 27. “We are pleased to have been added to the Russell 3000 and 2000 indexes, a milestone wh... Read MoreAxsome Therapeutics to Present at the 2016 JMP Securities Life Sciences Conference June 13, 2016NEW YORK, June 13, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome's Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on June 22, 2016 at 2:30 PM Eastern Time. Dr. Tabuteau will provide an overview of Axsome's business and late-stage clinical product candid... Read MoreAxsome Therapeutics Reports First Quarter 2016 Financial ResultsMay 11, 2016NEW YORK, May 11, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the quarter ended March 31, 2016. “We continued to make progress with our lead product candidates, AXS-02 and AXS-05, over the past quarter,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome Therapeutics. “We recently advanced A... Read MoreAxsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow LesionsMay 3, 2016NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received from the U.S. Food and Drug Administration (FDA) Fast Track designation for AXS-02 for the treatment of the pain of knee osteoarthritis (OA) associated with bone marrow lesions (BMLs). There is currently no product approved specifically for this indication. “We are plea... Read MoreAxsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s DiseaseApril 20, 2016Phase 2/3 Trial Planned in Agitation in Alzheimer’s Disease IND Submission Expected in 2016 NEW YORK, April 20, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received, from the U.S. Food and Drug Administration (FDA), Pre-Investigational New Drug Application (Pre-IND) written guidance on Axsome’s proposed clinical developmental plan for AX... Read MoreAxsome Therapeutics to Present at the 15th Annual Needham Healthcare ConferenceApril 4, 2016NEW YORK, April 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at 4:20 PM Eastern Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clinical product candi... Read MoreAxsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow LesionsMarch 28, 2016First Patient Enrolled in the COAST-1 Study Non-Opioid, Oral, Targeted, Potentially First-in-Class Mechanism for Pain Novel Biomarker-Based Approach for the Treatment of Knee Osteoarthritis Pain COAST-1 Study Being Conducted under FDA Special Protocol Assessment NEW YORK, March 28, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled th... Read MoreAxsome Therapeutics Reports Fourth Quarter and Full Year 2015 Financial ResultsMarch 24, 2016NEW YORK, March 24, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2015. “2015 was a pivotal year for Axsome as we accomplished a number of important milestones including initiating our Phase 3 trial with AXS-02 in complex regional pain syndrome, as well as co... Read MoreAxsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant DepressionMarch 17, 2016First Patient Enrolled in the STRIDE-1 Study Second Product Candidate Axsome Has Advanced into a Pivotal Trial NEW YORK , March 17, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in the STRIDE-1 (Symptom Treatment in Resistant Depression 1) study, a Phase 3 trial evaluating the efficacy and safety o... Read MoreAxsome Therapeutics Receives New U.S. Patent Covering AXS-02 for the Treatment of Complex Regional Pain SyndromeMarch 15, 2016Provides Patent Protection for AXS-02 into 2033 Covers Uses of Oral Zoledronic Acid for Complex Regional Pain Syndrome Represents the 19th Issued Patent Covering AXS-02 or Related Compounds NEW YORK, March 15, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, received a new patent (U.S. Patent No. 9,283,239), titled “Compositions for Ora... Read MoreAxsome Therapeutics to Present at the 2016 BIO CEO & Investor ConferenceFebruary 1, 2016NEW YORK, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 at 9:30 AM Eastern Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clinical product ca... Read MoreAxsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the KneeJanuary 27, 2016Provides Patent Protection into 2033NEW YORK, Jan. 27, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Patent and Trademark Office has issued a patent (U.S. Patent No. 9,211,257), which provides coverage for AXS-02, one of Axsome’s late-stage product candidates. The patented claims cover the use of zoledronic acid, the... Read MoreAxsome Therapeutics to Present at Biotech Showcase 2016January 4, 2016NEW YORK, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present at the 8th Annual Biotech Showcase 2016 conference on January 13, 2016 at 10:00 AM Pacific Time. Dr. Tabuteau will provide an overview of Axsome’s business and late-stage clini... Read More
Print PageE-mail PageRSS FeedsE-mail AlertsFinancial Tear Sheet